# A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

> **NCT04204161** · PHASE1 · UNKNOWN · sponsor: **Shenzhen BinDeBio Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood
- Refractory B-cell Acute Lymphoblastic Leukemia, Childhood
- Relapsed/Refractory B-cell Lymphoma, Childhood

## Interventions

- **BIOLOGICAL:** CAR-T19/CAR-T22

## Key facts

- **NCT ID:** NCT04204161
- **Lead sponsor:** Shenzhen BinDeBio Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-08
- **Primary completion:** 2021-10-30
- **Final completion:** 2024-10-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04204161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04204161, "A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04204161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*